Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
Name (Synonyms) | Correlation | |
---|---|---|
drug3923 | mRNA-1273 Wiki | 0.44 |
drug3408 | Three doses of placebo at the schedule of day 0, 14, 28 #High-dose group# Wiki | 0.38 |
drug103 | ARCT-021 single dose priming Wiki | 0.38 |
Name (Synonyms) | Correlation | |
---|---|---|
drug3510 | Two doses of middle-dose recombinant SARS-CoV-2 vaccine (CHO Cell) at the schedule of day 0, 14 Wiki | 0.38 |
drug3517 | Two doses of placebo at the schedule of day 0, 14 #middle-dose group# Wiki | 0.38 |
drug457 | Biological: mRNA-1273: 50 mcg Wiki | 0.38 |
drug3409 | Three doses of placebo at the schedule of day 0, 14, 28 #middle-dose group# Wiki | 0.38 |
drug1325 | Flu shot Wiki | 0.38 |
drug2504 | Placebo (two doses), priming Wiki | 0.38 |
drug3519 | Two doses of placebo at the schedule of day 0, 28(middle-dose group) Wiki | 0.38 |
drug3406 | Three doses of high-dose recombinant SARS-CoV-2 vaccine (Sf9 Cell) at the schedule of day 0, 14, 28 Wiki | 0.38 |
drug1921 | MMR vaccine Wiki | 0.38 |
drug456 | Biological: mRNA-1273: 100 mcg Wiki | 0.38 |
drug3407 | Three doses of middle-dose recombinant SARS-CoV-2 vaccine (CHO Cell) at the schedule of day 0, 14, 28 Wiki | 0.38 |
drug3518 | Two doses of placebo at the schedule of day 0, 28(high-dose group) Wiki | 0.38 |
drug3410 | Three doses of placebo at the schedule of day 0, 14, 28(high-dose group) Wiki | 0.38 |
drug2787 | Randomized booster Wiki | 0.38 |
drug3504 | Two doses of high-dose recombinant SARS-CoV-2 vaccine (CHO Cell) at the schedule of day 0, 14 Wiki | 0.38 |
drug3511 | Two doses of middle-dose recombinant SARS-CoV-2 vaccine (Sf9 Cell) at the schedule of day 0, 28 Wiki | 0.38 |
drug105 | ARCT-021 two lower dose priming Wiki | 0.38 |
drug104 | ARCT-021 two higher dose priming Wiki | 0.38 |
drug3405 | Three doses of high-dose recombinant SARS-CoV-2 vaccine (CHO Cell) at the schedule of day 0, 14, 28 Wiki | 0.38 |
drug3516 | Two doses of placebo at the schedule of day 0, 14 #High-dose group# Wiki | 0.38 |
drug3505 | Two doses of high-dose recombinant SARS-CoV-2 vaccine (Sf9 Cell) at the schedule of day 0, 28 Wiki | 0.38 |
drug2530 | Placebo booster Wiki | 0.38 |
drug2490 | Placebo Wiki | 0.24 |
drug1642 | Inactivated SARS-CoV-2 Vaccine (Vero cell) Wiki | 0.22 |
drug157 | Ad26.COV2.S Wiki | 0.22 |
Navigate: Correlations HPO
There are 7 clinical trials
This is a multicenter, randomized, double blind, parallel placebo controlled, phase 3 clinical trial to evaluate the protective efficacy, safety and immunogenicity of inactivated SARS-CoV-2 vaccines in healthy population 18 years old and above.
The mRNA-1273 vaccine is being developed to prevent COVID-19, the disease resulting from Severe Acute Respiratory Syndrome coronavirus (SARS-CoV-2) infection. The study is designed to primarily evaluate the efficacy, safety, and immunogenicity of mRNA-1273 to prevent COVID-19 for up to 2 years after the second dose of mRNA-1273.
Description: Clinical signs indicative of severe COVID-19 as predefined for the study.
Measure: Number of Participants with a First Occurrence of Severe COVID-19 Starting 14 Days after Second Dose of mRNA-1273 Time: Day 29 (second dose) up to Day 759 (2 years after second dose)Description: Clinical signs indicative of COVID-19 and SARS-CoV-2 Infection as predefined for the study.
Measure: Number of Participants with a First Occurrence of Either COVID-19 or SARS-CoV-2 Infection regardless of symptomatology or Severity Starting 14 Days after Second Dose of mRNA-1273 or Placebo Time: Day 29 (second dose) up to Day 759 (2 years after second dose)]Description: Clinical signs indicative of secondary case definition of COVID-19 as predefined for the study.
Measure: Number of Participants with a Secondary Case Definition of COVID-19 Starting 14 days after Second Dose of mRNA-1273 or Placebo Time: Day 29 (second dose) up to Day 759 (2 years after second dose)Description: Clinical signs indicative of COVID-19 as predefined for the study.
Measure: Number of Participants with a First Occurrence of COVID-19 Starting 14 days after First Dose of mRNA-1273 or Placebo Time: Day 1 (first dose) up to Day 759 (2 years after second dose)Description: Clinical signs indicative of COVID-19 and SARS-CoV-2 infection as predefined for the study.
Measure: Number of Participants with a First Occurrence of COVID-19 Starting 14 days after Second Dose of mRNA-1273 or Placebo regardless of evidence of prior SARS-CoV-2 Infection Time: Day 29 (second dose) up to Day 759 (2 years after second dose)Description: Clinical signs indicative of COVID-19 and SARS-CoV-2 infection as predefined for the study.
Measure: Number of Participants with a First Occurrence of SARS-CoV-2 Infection in the Absence of Symptoms Defining COVID-19 Starting 14 days after Second Dose of mRNA-1273 or Placebo Time: Day 29 (second dose) up to Day 759 (2 years after second dose)The mRNA-1273 vaccine is being developed to prevent COVID-19, the disease resulting from Severe Acute Respiratory Syndrome coronavirus (SARS-CoV-2) infection. The study is designed to primarily evaluate the safety and reactogenicity of a single dose level of mRNA-1273 vaccine administered in 2 doses 28 days apart to an adolescent population.
Description: Acceptable serum Ab threshold as predefined for the study.
Measure: Number of Participants Who have Reached the Acceptable Threshold for the Serum Ab Level at Day 57 Time: Day 57 (28 days after second dose)Description: Clinical signs indicative of SARS-CoV-2 infection as predefined for the study.
Measure: Number of Participants with a SARS-CoV-2 Infection Starting on Day 57 Time: Day 57 up to Day 394Description: Clinical signs indicative of COVID-19 as predefined for the study.
Measure: Number of Participants with a First Occurrence of COVID-19 Starting 14 days after Second Dose of mRNA-1273 or Placebo Time: Day 29 (second dose) up to Day 394 (1 year after second dose)This clinical study will assess the safety, reactogenicity, and immunogenicity of 2 dose levels of mRNA-1273 SARS-COV-2 vaccine in adults 18 years of age or older.
Description: Seroconversion as measured by an increase of SARS-CoV-2-specific neutralizing antibody (nAb) titer either from below the limit of detection (LOD) or lower limit of quantification (LLOQ) to equal to or above LOD or LLOQ, or a 4-times higher titer in participants with pre-existing nAb titers.
Measure: Seroconversion as measured by an increase of SARS-CoV-2-specific neutralizing antibody (nAb) titer Time: Through 1 year post last vaccinationThis is a phase I, single-center, randomized, placebo-controlled, double-blind study, to evaluate safety, tolerability and immunogenicity of a recombinant SARS-CoV-2 vaccine (Sf9 cell) in Chinese healthy population aged 18 years and older. After randomization, the trial for each subject will last for approximately 13 months. Screening period is 1 week prior to randomization (Day -7 to Day -1), and each dose of either SARS-CoV-2 vaccine (Sf9 Cell) or placebo will be given intramuscularly (IM) on Day 0 and Day 28 for a two-dose regimen, or on Day 0, Day 14, and Day 28 for a three-dose regimen. Subjects who are ≥18 years old and ≤ 55 years old will be enrolled in adult group, and healthy elderly population who are >55 years old will be enrolled in elderly group. After adult group completes the follow-up 7 days after first vaccination, elderly group will be recruited.
Description: Occurrence of solicited AR in the subjects within 7 days after each dose of recombinant SARS-CoV-2 vaccine (Sf9 cell) or placebo.
Measure: Occurrence of adverse reactions (AR) within 7 days after each dose of the recombinant SARS-CoV-2 vaccine (Sf9 cell) or placebo. Time: 7 days after each dose.Description: Occurrence of solicited AE in the subjects within 7 days after each dose of recombinant SARS-CoV-2 vaccine (Sf9 cell) or placebo.
Measure: Occurrence of adverse events (AE) within 7 days after each dose of the recombinant SARS-CoV-2 vaccine (Sf9 cell) or placebo. Time: 7 days after each dose.Description: Occurrence of subjects experiencing AE associated with recombinant SARS-CoV-2 vaccine (Sf9 cell) up to Day 28.
Measure: Occurrence of AE up to Day 28 after prime and boost vaccination. Time: Day 28 after prime and boost vaccination.Description: The proportion of subjects experiencing SAEs up to Day 28 after prime and boost vaccination.
Measure: The proportion of SAEs up to Day 28 after prime and boost vaccination. Time: Day 28 after prime and boost vaccination.Description: Month 12 after prime and boost vaccination.
Measure: The proportion of SAEs up to Month 12 after prime and boost vaccination. Time: The proportion of subjects experiencing SAEs up to Month 12 after prime and boost vaccination.Description: The proportion of subjects experiencing abnormal markers of hematology, blood chemistry and urine analysis within 7 days before prime vaccination and at Day 3 after each dose of recombinant SARS-CoV-2 vaccine (Sf9 cell) or placebo.
Measure: The proportion of abnormal markers of hematology, blood chemistry and urine analysis within 7 days before prime vaccination and at Day 3 after each dose of recombinant SARS-CoV-2 vaccine (Sf9 cell) or placebo. Time: 7 days before prime vaccination and Day 3 after each dose.Description: Geometric mean titer (GMT) of anti-RBD specific antibody at Day 7, Day 14, Day 28, Month 3, Month 6, and Month 12 after boost vaccination.
Measure: GMT of anti-RBD specific antibody at Day 7, Day 14, Day 28, Month 3, Month 6, and Month 12 after boost vaccination. Time: Day 7, Day 14, Day 28, Month 3, Month 6, and Month 12 after boost vaccination.Description: Four-fold increase in anti-RBD specific antibody titers, as compared to baseline, at Day 7, Day 14, Day 28, Month 3, Month 6, and Month 12 after boost vaccination.
Measure: Four-fold increase in anti-RBD specific antibody titers, at Day 7, Day 14, Day 28, Month 3, Month 6, and Month 12 after boost vaccination. Time: Day 7, Day 14, Day 28, Month 3, Month 6, and Month 12 after boost vaccination.Description: Geometric mean fold increase (GMFI) of anti-RBD specific antibody at Day 7, Day 14, Day 28, Month 3, Month 6, and Month 12 after boost vaccination.
Measure: GMFI of anti-RBD specific antibody at Day 7, Day 14, Day 28, Month 3, Month 6, and Month 12 after boost vaccination. Time: Day 7, Day 14, Day 28, Month 3, Month 6, and Month 12 after boost vaccination.Description: Geometric mean titer (GMT) of SARS-CoV-2 neutralizing antibody (including pseudovirus and live virus-based SARS-CoV-2 neutralizing antibody assay) at Day 7, Day 14, Day 28, Month 3, Month 6, and Month 12 after prime and boost vaccination.
Measure: GMT of SARS-CoV-2 neutralizing antibody at Day 7, Day 14, Day 28, Month 3, Month 6, and Month 12 after boost vaccination. Time: Day 7, Day 14, Day 28, Month 3, Month 6, and Month 12 after boost vaccination.Description: Four-fold increase in SARS-CoV-2 neutralizing antibody titers (including pseudovirus and live virus-based SARS-CoV-2 neutralizing antibody assay), as compared to baseline, at Day 7, Day 14, Day 28, Month 3, Month 6, and Month 12 after boost vaccination.
Measure: Four-fold increase in SARS-CoV-2 neutralizing antibody titers, at Day 7, Day 14, Day 28, Month 3, Month 6, and Month 12 after boost vaccination. Time: Day 7, Day 14, Day 28, Month 3, Month 6, and Month 12 after boost vaccination.Description: Geometric mean fold increase (GMFI) of SARS-CoV-2 neutralizing antibody (including pseudovirus and live virus-based SARS-CoV-2 neutralizing antibody assay) at Day 7, Day 14, Day 28, Month 3, Month 6, and Month 12 after boost vaccination.
Measure: GMFI of SARS-CoV-2 neutralizing antibody at Day 7, Day 14, Day 28, Month 3, Month 6, and Month 12 after prime and boost vaccination. Time: Day 7, Day 14, Day 28, Month 3, Month 6, and Month 12 after boost vaccination.Description: Seroconversion rates of IFN-γ stimulated by the overlapping peptide library of S-RBD protein at Day 14, Day 28 after boost vaccination.
Measure: Seroconversion rates of IFN-γ stimulated by the overlapping peptide library of S-RBD protein at Day 14, Day 28 after boost vaccination. Time: Day 14, Day 28 after boost vaccination.This is a phase I, randomized, placebo-controlled, double-blind study, to evaluate safety and immunogenicity of a recombinant SARS-CoV-2 vaccine (CHO cell) in Chinese healthy population aged 18 years and older. After randomization, the trial for each subject will last for approximately 13 months. Screening period is 1 week prior to randomization (Day -7 to Day -1), and each dose of either SARS-CoV-2 vaccine (CHO Cell) or placebo will be given intramuscularly (IM) on Day 0 and Day 14 for a two-dose regimen, or on Day 0, Day 14, and Day 28 for a three-dose regimen. Subjects who are ≥18 years old and ≤ 59 years old will be enrolled in adult group, and healthy elderly population who are >59 years old will be enrolled in elderly group. After adult group completes the follow-up 7 days after first vaccination, elderly group will be recruited.
Description: The units of IL2 and IL6 are both pg/ml
Measure: Changes in serum cytokine (IL2, IL6) levels from baseline after 3 days of each dose Time: 3 days of each doseThis is a Phase 2, randomized, placebo-controlled, and observer-blind study in healthy adults. The study will evaluate the safety, tolerability, and immunogenicity of the SARS-CoV-2 RNA vaccine candidate against COVID-19: As 2 doses (at two different dose levels), separated by 28 days or as 1 dose In adults 18 years of age and older
Description: Adverse events reported daily in a diary that reflect common symptoms or findings at the injection site following vaccination
Measure: Percentages of participants reporting solicited local adverse events Time: for 7 days following each dose administrationDescription: Adverse events reported daily in a diary that reflect generalized symptoms following vaccination
Measure: Percentages of participants reporting solicited systemic adverse events Time: for 7 days following each dose administrationDescription: spontaneously reported adverse events
Measure: Percentages of participants reporting adverse events Time: 28 days following each dose administrationDescription: unsolicited adverse events that meet the definition of serious
Measure: Percentages of participants reporting serious adverse events Time: Day 0 to Day 388Description: unsolicited adverse events that lead to healthcare provider visit
Measure: Percentages of participants reporting medically attended adverse events Time: Day 0 to Day 388Description: unsolicited adverse events associated with new diagnosis of chronic disease
Measure: Percentages of participants reporting new onset of chronic disease Time: Day 0 to Day 388Description: chemistry and hematology
Measure: Percentages of participants with abnormal chemistry and hematology values Time: Day 0 to Day 215Description: neutralizing antibody response
Measure: SARS-CoV-2 serum neutralizing antibody levels, expressed as GMTs Time: Day 0 to Day 388Description: neutralizing antibody response
Measure: Changes in SARS-CoV-2 serum neutralizing titers from before vaccination to each subsequent time point, expressed as GMFRs Time: Through Day 388Description: neutralizing antibody response
Measure: Percentages of participants achieving greater than or equal to 2-fold and 4-fold rises from before vaccination in SARS-CoV-2 serum neutralizing antibody levels Time: Through Day 388Description: SARS-CoV-2 anti S1, RBD, N binding antibody responses
Measure: SARS-CoV-2 anti-S1, anti-RBD, and anti-N binding antibody levels, expressed as GMCs Time: Day 0 to Day 388Description: SARS-CoV-2 anti S1, RBD, N binding antibody responses
Measure: Changes in SARS-CoV-2 anti-S1, anti-RBD, and anti-N binding antibody levels from before vaccination to each subsequent time point, expressed as GMFRs Time: Through Day 388Description: SARS-CoV-2 anti S1, RBD, N binding antibody responses
Measure: Percentages of participants achieving greater than or equal to 2-fold and 4-fold rises from before vaccination in SARS-CoV-2 SARS-CoV-2 anti-S1, anti-RBD, and anti-N binding antibody levels Time: Through Day 388Alphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on January 01, 2021.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports